- Home
- JLL vs FMS Comparison
JLL vs FMS Comparison
Compare JLL & FMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JLL | FMS |
|---|---|---|
| Founded | 1997 | 1996 |
| Country | United States | Germany |
| Employees | 48000 | N/A |
| Industry | Real Estate | Misc Health and Biotechnology Services |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.8B | 14.2B |
| IPO Year | 1997 | N/A |
Fundamental Metrics
Financial Performance| Metric | JLL | FMS |
|---|---|---|
| Price | $352.14 | $23.17 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 7 | 2 |
| Target Price | ★ $362.00 | $30.00 |
| AVG Volume (30 Days) | 356.6K | ★ 436.8K |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 2.44% |
| EPS Growth | ★ 45.13 | N/A |
| EPS | ★ 16.40 | N/A |
| Revenue | ★ $26,115,600,000.00 | N/A |
| Revenue This Year | $7.70 | N/A |
| Revenue Next Year | $6.91 | $3.83 |
| P/E Ratio | $21.12 | ★ $15.62 |
| Revenue Growth | ★ 11.45 | N/A |
| 52 Week Low | $207.92 | $20.96 |
| 52 Week High | $363.06 | $30.46 |
Technical Indicators
Market Signals| Indicator | JLL | FMS |
|---|---|---|
| Relative Strength Index (RSI) | 78.18 | 52.96 |
| Support Level | $334.29 | $22.50 |
| Resistance Level | $359.82 | $23.36 |
| Average True Range (ATR) | 8.35 | 0.38 |
| MACD | 4.99 | 0.06 |
| Stochastic Oscillator | 99.91 | 64.29 |
Price Performance
Historical ComparisonAbout JLL Jones Lang LaSalle Incorporated
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $74 billion for clients across diverse public and private real estate strategies.
About FMS Fresenius Medical Care AG
Fresenius Medical Care is the largest dialysis company in the world, treating about 300,000 patients from nearly 3,700 clinics worldwide as of December 2024. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.